Cullinan Therapeutics, Inc. (CGEM)

17,95 +0,33 (+1,87%) Börsenschluss: 04:00PM EDT

Cullinan Therapeutics, Inc.

One Main Street
Suite 1350
Cambridge, MA 02142
United States
617 410 4650
https://cullinantherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 85

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Nadim Ahmed	President, CEO & Director	1,16M	N/A	1968
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.	Chief Medical Officer	780,32k	N/A	1971
Dr. Patrick A. Baeuerle Ph.D.	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board	763,73k	N/A	1958
Ms. Mary Kay Fenton	Chief Financial Officer	N/A	N/A	1964
Dr. Jennifer Michaelson Ph.D.	Chief Scientific Officer	N/A	N/A	1967
Ms. Jacquelyn L. Sumer J.D.	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	N/A	N/A	1978
Ms. Rose Weldon	Senior Vice President of Communications	N/A	N/A	N/A
Mr. Steve Andre	Chief Human Resources Officer	N/A	N/A	N/A
Dr. Corinne Savill Ph.D.	Chief Business Officer	N/A	N/A	1959
Mr. Kevin A. Johnston	Chief Technical Operations Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cullinan Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. September 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.